Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7585628 | 0.82 | GAA (0.58) | GAAMAPTCYP3A4TP53ALDH1A1 | |
| SCHEMBL7780561 | 0.82 | CYP3A4 (0.45) | GAAMAPTCYP3A4TP53ALDH1A1 | |
| SCHEMBL31619139 | 0.75 | CYP3A4 (0.38) | GAACYP3A4ALDH1A1KDM1AKDM1B | |
| SCHEMBL263907 | 0.75 | PDK2 (0.37) | ALDH1A1KDM1AKDM1B | |
| SCHEMBL29428923 | 0.75 | MAPT (0.37) | GAAMAPTALDH1A1KDM1AKDM1B | |
| SCHEMBL31246242 | 0.75 | CYP3A4 (0.50) | GAACYP3A4TP53ALDH1A1CA1 | |
| SCHEMBL20303393 | 0.75 | MAPT (0.37) | GAAMAPTALDH1A1KDM1AKDM1B | |
| SCHEMBL21050901 | 0.75 | CYP3A4 (0.50) | GAAMAPTCYP3A4TP53ALDH1A1 | |
| SCHEMBL15573666 | 0.75 | GAA (0.50) | GAAMAPTCA1CA2CA9 | |
| SCHEMBL17964095 | 0.75 | CYP3A4 (0.50) | GAACYP3A4TP53ALDH1A1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346606-A1 | CAMPTOTHECIN COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-11-13 | — | — | US | disclosed |
| US-20250281631-A1 | ANTIBODY-DRUG CONJUGATES AND PREPARATION METHODS AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-09-11 | — | — | US | disclosed |
| EP-4601701-A1 | ANTIBODY-DRUG CONJUGATE BINDING TO HUMAN PTK7 AND METHOD FOR PREPARATION AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-08-20 | — | — | EP | disclosed |
| CN-120058723-A | Camptothecins compound and its preparation method and application | 四川科伦博泰生物医药股份有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-119997983-A | Antibody drug conjugate, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-119899238-A | Condensed-cyclic compound, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-117567478-B | Camptothecins compound and its preparation method and application | 四川科伦博泰生物医药股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| WO-2025045015-A1 | ANTIBODY-DRUG CONJUGATE AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2025-03-06 | — | — | WO | disclosed |
| EP-4514396-A1 | ANTIBODY-DRUG CONJUGATES AND PREPARATION METHODS AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-03-05 | — | — | EP | disclosed |
| US-20250017914-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. | 2025-01-16 | — | — | US | disclosed |
| CN-116829561-A | Camptothecins compound and its preparation method and application | 四川科伦博泰生物医药股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023039505-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | WO | disclosed |
| CN-115490709-A | KRASG12D inhibitor and application thereof in medicine | 四川海思科制药有限公司 | 2022-12-20 | — | — | CN | disclosed |
| WO-2022253035-A1 | ANTIBODY DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2022-12-08 | — | — | WO | disclosed |
| WO-2021063346-A1 | KRAS G12C INHIBITOR AND APPLICATION THEREOF | 上海迪诺医药科技有限公司 | 2021-04-08 | — | — | WO | disclosed |
| US-10597405-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2020-03-24 | — | — | US | disclosed |
| US-20190177338-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | US | disclosed |
| WO-2019110751-A1 | TETRACYCLIC COMPOUNDS AS INHIBITORS OF G12C MUTANT RAS PROTEIN, FOR USE AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | WO | disclosed |
| WO-2019110751-A1 | TETRACYCLIC COMPOUNDS AS INHIBITORS OF G12C MUTANT RAS PROTEIN, FOR USE AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | WO | disclosed |
| US-20190177338-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177338-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | GAA 238/4885MAPT 2445/4885CYP3A4 322/4885 |
| US-20250346606-A1 | CAMPTOTHECIN COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | WEE1, WEE2, PCLAF | GAA 1215/4885MAPT 4190/4885CYP3A4 2902/4885 |
| US-10597405-B2 | Chemical compounds | MKI67, CCNI, MCL1 | GAA 238/4885MAPT 2445/4885CYP3A4 322/4885 |
| US-20250017914-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | TOP2A, TOP2B, UGT2B7 | GAA 331/4885MAPT 4787/4885CYP3A4 89/4885 |
| US-20250281631-A1 | ANTIBODY-DRUG CONJUGATES AND PREPARATION METHODS AND USE THEREOF | TOP1, TOP2A, TOP2B | GAA 605/4885MAPT 3156/4885CYP3A4 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.